Medically reviewed by Matthew Wosnitzer, MD Key Takeaways Metastatic castration-resistant prostate cancer is an advanced form ...

TALAPRO-2 trial shows Talzenna plus Xtandi improves median OS by 8.8 months in mCRPC patients, reducing death risk by 20.4%. HRR-deficient patients benefit more, with a 38% reduction in death risk and ...

Experts project the diagnosis of over 300,000 prostate cancer cases in the United States in 2006, along with over 30,000 ...

Recently, the standard of care for metastatic Castration Resistant Prostate Cancer (mCRPC) has changed considerably. Persistent androgen receptor (AR) signaling has been identified as a target for ...

The investigational drug BMS-986365 may help patients with mCRPC previously treated with ARPIs overcome drug resistance, despite their genomic status. The investigational dual androgen receptor ...

Clinical and pathologic characteristics of mCRPC were largely similar between younger and older patients. Overall survival was not significantly different between younger and older patients with mCRPC ...

BOSTON, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Halda Therapeutics today announced that new clinical data on HLD-0915, the company’s first-in-class oral RIPTAC™ therapeutic, will be presented at the plenary ...

BRCA- and tumor suppressor gene mutations are associated with worse overall survival among patients receiving lutetium-177 PSMA radioligand therapy for mCRPC. Lutetium-177-PMSA radioligand therapy (Lu ...

Metastatic castration-resistant prostate cancer (mCRPC) is a type of advanced prostate cancer that has spread to other parts of the body. It no longer responds to treatments that block testosterone, a ...